MHRA centralizes real-world evidence guidance for UK medicine and device decisions
The Medicines and Healthcare products Regulatory Agency has launched a Real-World Evidence knowledge and guidance hub designed to bring together its guidance, publications, and resources on the use of real-world data in regulatory decision-making for medicines and medical devices in the UK.
The move is administrative on the surface, but clinically consequential in practice. Regulatory systems increasingly depend on evidence generated outside traditional randomized trials, especially when questions involve long-term safety, rare outcomes, treatment patterns in routine care, or device performance after market entry. By collecting the agency’s material in one place, the hub gives researchers, healthcare professionals, industry, patients, and other stakeholders a common starting point for understanding how the MHRA thinks about real-world data and real-world evidence.
Real-world data, in the MHRA’s framing, are data relating to patient health status or delivery of health care that are collected outside a clinical study. Once those data are analyzed, the resulting information becomes real-world evidence. The distinction is simple but important. Data are the raw clinical traces of care; evidence emerges only after those traces are structured, interpreted, and applied to a regulatory question.
For regulators, the attraction of RWE lies in what clinical trials often cannot fully capture. Trial populations are selected, follow-up windows are finite, and protocol-driven conditions can differ sharply from daily practice. Routine-care data can reveal how a medicine is used across broader patient groups, how a device behaves in mixed clinical settings, and where benefits or harms appear once a product leaves the controlled environment of pre-approval testing. In that sense, the MHRA hub reflects an effort to organize an evidence type that is becoming harder to ignore.
The agency’s choice of language is also revealing. By explicitly defining RWD as information collected outside a clinical study, the guidance hub reinforces the boundary between interventional research and observational information streams. That boundary matters in regulation because the quality of any analysis depends on the provenance of the underlying data, the completeness of the record, the consistency of measurement, and the clinical question being asked. A hospital database, an insurance claim, an electronic health record, and a post-market registry may all qualify as sources of RWD, yet each carries different strengths and vulnerabilities.
RWE can support regulatory decision-making, but only when the underlying dataset is fit for purpose. Missing outcomes, inconsistent coding, confounding by indication, and treatment-selection bias can distort results if studies are poorly designed or interpreted too aggressively. That is why a hub dedicated to knowledge and guidance has practical value beyond simple document storage: it can shape expectations about what RWD can and cannot answer, and it can help stakeholders align methods with regulatory intent.
For medicines, RWE is often most persuasive when it addresses questions that extend beyond efficacy under trial conditions. Those questions may include persistence of use, medication adherence in routine practice, safety in broader populations, and comparative performance across care settings. For medical devices, the same logic can apply to durability, usability, operator dependence, and real-world complication profiles after deployment. In both domains, the regulatory promise of RWE is not to replace trials, but to complement them with context drawn from actual care delivery.
The hub is aimed at a wide audience, and that breadth is itself instructive. Researchers need methodological clarity; healthcare professionals need to understand how evidence may influence practice and licensing; industry needs a regulatory frame for submissions and lifecycle evidence planning; patients and other stakeholders need transparency about how decisions are informed. When those groups work from the same repository of guidance, the conversation around evidence becomes less fragmented and more actionable.
The agency also added a link to a data requirements page on 9 October 2026, the same date the page was first published. That update suggests the hub is intended to be a living resource rather than a static notice. In the regulatory setting, living resources matter because data standards, analytics approaches, and evidence expectations evolve quickly as electronic health records, linked datasets, and post-market surveillance tools become more sophisticated.
One sentence captures the practical significance: this is an infrastructure play for evidence generation.
The most important question is not whether RWE will matter, but how carefully it will be governed. Real-world datasets can strengthen medicine and device regulation when they are transparent, reproducible, and clinically interpretable. They can also mislead when assumptions outpace the quality of the underlying data. The MHRA hub signals that the agency wants those issues addressed in one organized place, with definitions and resources that can support more consistent use across the UK regulatory system.
What remains open is how the guidance will be operationalized in specific applications, and how much weight different forms of RWE will carry when stacked against trial evidence. The page establishes the framework and the terminology. The harder work will come in the studies, submissions, and regulatory decisions that rely on it.